Health Affairs  |  June 7, 2023

Read the Publication

After years of legislative failures amidst aggressive industry lobbying, the passage of the Inflation Reduction Act (IRA) finally empowered Medicare to negotiate the price of certain single-source, high-priced drugs. In recent months, and now, with the first lawsuit filed by Merck on June 6, 2023, the pharmaceutical industry has begun to preview a slew of potential constitutional and statutory legal claims that could jeopardize the implementation of the signature health care achievement enacted under the IRA.

Read more here.

Related Initiatives

Health Policy and the Law